Latest Revenue Growth News

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.

BTC Health reports a strong FY25 with a $4 million statutory profit, boosted by a $5 million contract and strategic acquisition. The company eyes further growth in FY26 with new product launches and expanded market reach.

NEXTDC’s FY25 results reveal robust financial growth driven by surging AI and cloud demand, alongside a strategic joint venture to expand its Western Sydney data centre footprint.

NEXTDC has delivered record FY25 financial results, surpassing revenue and EBITDA guidance while aggressively expanding its data centre footprint across Australia and Asia-Pacific. The company’s strengthened liquidity and strategic investments position it to capitalise on soaring AI and cloud demand.

McMillan Shakespeare Limited reported steady FY25 growth with Normalised UNPATA of $103.2 million and an 8.3% dividend yield, underpinned by digital innovation and strategic investments.

NEXTDC Limited reported a 6% rise in FY25 revenue and underlying EBITDA, offset by a widened loss due to a $2.9 billion debt refinancing. The company’s strategic expansion in AI-ready data centres and a strengthened $6.4 billion debt facility position it for significant growth.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit for FY25, marking the completion of its transformative Simply Stronger program that enhanced digital offerings and customer reach.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.

PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Mad Paws Holdings reported a 14% revenue increase and improved EBITDA margins in FY25, while preparing to sell its marketplace business to Rover Group and exit e-commerce operations.

Simble Solutions Limited reported a 21.3% revenue decline and a $646,578 net loss for H1 2025, while raising $807,375 to fund strategic growth in renewable energy and AI integration.